Jeminiwa Ruth, Hohmann Natalie S, Hastings Tessa J, Hansen Richard, Qian Jingjing, Garza Kimberly B
J Am Pharm Assoc (2003). 2022 Jan-Feb;62(1):134-141.e1. doi: 10.1016/j.japh.2021.09.001. Epub 2021 Sep 8.
Patients with chronic conditions continue to face financial and system-related barriers to medication adherence. Pharmacy, provider, and payer-based financial and social incentive-based interventions may reduce these barriers and improve adherence. However, it is unclear how patient demographics and clinical characteristics influence the type of incentives preferred by patients.
To examine individuals' preference for financial versus social incentives and to explore the association between patient demographic and clinical characteristics with preferences for financial or social incentives.
A cross-sectional survey of a nationally representative sample of patients was conducted with Qualtrics panelists (N = 909). U.S. adults taking at least 1 prescription medication for a chronic condition were included. Survey items elicited participants' demographic characteristics, preference for financial or social incentives, self-reported medication adherence, number of prescribed medications, and number of chronic conditions. Bivariate associations between patient characteristics and incentive preferences were tested using t and chi-square tests. Logistic regression was performed to determine patient characteristics associated with participants' preference for incentives.
When compared with those who were adherent to medications, individuals who were nonadherent were less likely to prefer financial incentives over social incentives (adjusted odds ratio [OR] 0.55 [95% CI 0.31-0.98]). Patient income, sex, and ethnicity were also associated with preferences for financial incentives. Those earning less than $50,000 per year were less likely to prefer financial incentives compared with social incentives (adjusted OR 0.44 [0.24-0.79]). Females were more likely to prefer financial incentives (adjusted OR 1.98 [1.16-3.37]). Hispanic/Latinos were less likely to prefer financial incentives compared to non-Hispanics/non-Latinos (adjusted OR 0.51 [0.29-0.89]).
Preferences for medication adherence incentives differed on the basis of adherence status and patients' demographic characteristics. Findings have implications for how incentive-based interventions can be structured to target certain patient groups.
慢性病患者在药物依从性方面仍然面临经济和系统相关的障碍。基于药房、医疗服务提供者和支付方的经济和社会激励干预措施可能会减少这些障碍并提高依从性。然而,尚不清楚患者的人口统计学特征和临床特征如何影响患者对激励措施类型的偏好。
研究个人对经济激励与社会激励的偏好,并探讨患者人口统计学特征和临床特征与经济或社会激励偏好之间的关联。
对Qualtrics小组成员进行了一项全国代表性患者样本的横断面调查(N = 909)。纳入了至少服用1种治疗慢性病的处方药的美国成年人。调查项目引出了参与者的人口统计学特征、对经济或社会激励的偏好、自我报告的药物依从性、处方药数量和慢性病数量。使用t检验和卡方检验来检验患者特征与激励偏好之间的双变量关联。进行逻辑回归以确定与参与者激励偏好相关的患者特征。
与坚持服药的人相比,不坚持服药的人不太可能更喜欢经济激励而非社会激励(调整后的优势比[OR]为0.55[95%CI 0.31 - 0.98])。患者收入、性别和种族也与经济激励偏好相关。与社会激励相比,年收入低于5万美元的人不太可能更喜欢经济激励(调整后的OR为0.44[0.24 - 0.79])。女性更有可能更喜欢经济激励(调整后的OR为1.98[1.16 - 3.37])。与非西班牙裔/非拉丁裔相比,西班牙裔/拉丁裔不太可能更喜欢经济激励(调整后的OR为0.51[0.29 - 0.89])。
药物依从性激励措施的偏好因依从状态和患者人口统计学特征而异。研究结果对如何构建基于激励的干预措施以针对特定患者群体具有启示意义。